A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...
A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.